Printer Friendly Version
Tolerability
The tolerability you want in a once-monthly, film-coated tablet
  • In the MOBILE trial, overall adverse events (AEs) for the 150-mg once-monthly dose were similar to the 2.5-mg daily dose

BONIVA 2.5 mg daily AEs similar to placebo

  • In the BONE trial, overall AEs for the 2.5-mg daily dose were similar to placebo
  • In patients taking aspirin, NSAIDs, PPIs and H2 blockers, the incidence of upper gastrointestinal (GI) AEs was similar to placebo
Chart: GI adverse events with an incidence >=5%*
*The Monthly Oral IBandronate In LadiEs (MOBILE) trial was a 2-year, randomized, double-blind, phase III, noninferiority trial designed to confirm that once-monthly dosing was as effective as daily dosing in increasing lumbar spine BMD at year 1. Women with postmenopausal osteoporosis (N=1609) were assigned to one of four oral ibandronate regimens including 2.5 mg daily (n=395) and 150 mg once-monthly (n=396). All patients took 400 IU vitamin D and 500 mg calcium supplementation each day.
Enlarge chart
  • Withdrawal rate due to AEs was 8% for 150 mg once-monthly and 9% for 2.5 mg daily
  • Patients with a history of GI disease and/or patients taking aspirin, NSAIDs, PPIs and H2 blockers were not excluded from the BONE and MOBILE trials

Contraindications

BONIVA tablets are contraindicated in patients unable to stand or sit upright for at least 60 minutes or with uncorrected hypocalcemia.

BONIVA is contraindicated in patients with known hypersensitivity to BONIVA or any of its components.

Osteoporosis Treatment